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Succinate supplementation 
improves metabolic performance 
of mixed glial cell cultures with 
mitochondrial dysfunction
Susan Giorgi-Coll1, Ana I. Amaral2, Peter J. A. Hutchinson1, Mark R. Kotter1,2 & Keri L. H. 
Carpenter1
Mitochondrial dysfunction, the inability to efficiently utilise metabolic fuels and oxygen, contributes 
to pathological changes following traumatic spinal cord or traumatic brain injury (TBI). In the present 
study, we tested the hypothesis that succinate supplementation can improve cellular energy state 
under metabolically stressed conditions in a robust, reductionist in vitro model of mitochondrial 
dysfunction in which primary mixed glial cultures (astrocytes, microglia and oligodendrocytes) 
were exposed to the mitochondrial complex I inhibitor rotenone. Cellular response was determined 
by measuring intracellular ATP, extracellular metabolites (glucose, lactate, pyruvate), and oxygen 
consumption rate (OCR). Rotenone produced no significant changes in glial ATP levels. However, 
it induced metabolic deficits as evidenced by lactate/pyruvate ratio (LPR) elevation (a clinically-
established biomarker for poor outcome in TBI) and decrease in OCR. Succinate addition partially 
ameliorated these metabolic deficits. We conclude that succinate can improve glial oxidative 
metabolism, consistent our previous findings in TBI patients’ brains. The mixed glial cellular model may 
be useful in developing therapeutic strategies for conditions involving mitochondrial dysfunction, such 
as TBI.
Following traumatic injury to the spinal cord or brain, a complex combination of pathological processes develop, 
in which cerebral energy perturbations and cellular metabolism play a key role1–5. Despite modern advances 
in acute neurocritical care, many traumatic brain injury (TBI) or spinal cord injury (SCI) patients who survive 
the injury experience long-term disability. Greater understanding of the pathophysiology of the injured central 
nervous system (CNS) is needed to improve early neurocritical care. Previous research has suggested that ‘mito-
chondrial dysfunction’, where the brain is unable to efficiently utilise metabolic fuels and oxygen despite adequate 
provision, may underlie damaging metabolic disturbances, which progress after injury. Notably, high brain extra-
cellular lactate/pyruvate ratio (LPR), suggestive of high glycolytic activity and reduced mitochondrial function, 
correlates with unfavourable clinical outcome4.
Early studies of cellular metabolism in the injured brain focussed on ischaemia, which has been minimised in 
the modern clinical care setting by maintaining adequate cerebral perfusion, as well as intracranial pressure below 
a critical threshold6. In the absence of ischaemia, mitochondrial dysfunction is thought to be responsible for 
energy perturbations in the brain after injury5, 7. A reduced Ca2+ uptake state after TBI is thought to be relevant 
here, as this results in an increase in Ca2+ in the cytosol, which is taken up by mitochondria with great efficiency at 
the expense of membrane potential. As a consequence, a condition termed Ca2+ overload develops, which is char-
acterised by reduced mitochondrial dehydrogenase activity and subsequent suboptimal mitochondrial-driven 
metabolism8–10. In addition, the production and activity of reactive oxygen species (ROS) is thought to play a key 
role, affecting mitochondrial membrane potential and damaging membrane-bound components10.
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Succinate plays a pivotal role in oxidative metabolism. Succinate is a tricarboxylic acid (TCA) cycle interme-
diate that interacts directly with the mitochondrial electron transport chain (ETC), enabling a ‘shortcut’ route to 
ATP production via oxidative metabolism. This has been suggested as a potential therapeutic strategy for TBI11. 
Succinate is converted to fumarate in the TCA cycle by complex II (succinate dehydrogenase (SDH)) of the ETC 
on the mitochondrial inner membrane12, 13. The remainder of the TCA cycle is driven by soluble mitochondrial 
enzymes, resulting in the production of NADH which interacts with complex I of the ETC12, 13. This in turn drives 
the ETC sequentially from complex I to Coenzyme Q (CoQ) through to culmination at complex IV, missing com-
plex II12, 13. Succinate, contrastingly, misses complex I and causes the ETC to run sequentially from complex II all 
the way through to complex IV (converting oxygen to water)12, 13.
Complex I of the ETC is known to be particularly vulnerable to dysfunction or damage, especially in the pres-
ence of ROS14. In bypassing complex I, succinate can provide a potential fuel source for compromised mitochon-
dria in order to produce ATP and maintain membrane potential. Preventing ATP levels from falling to critically 
low levels is crucial in blocking the activation of cell death pathways that would result in loss of brain tissue. The 
strategy of ‘bypassing’ defective ETC components was first reported by Eleff et al., who demonstrated that muscle 
ATP synthesis in a patient with a genetically defective form of complex III could be maintained by supplemen-
tation with vitamins C and K15. In other studies, infusion of succinate, which bypasses complex I, prevented 
decline in liver ATP levels and prolonged survival in cases of experimental sepsis, a pathology involving energy 
dysfunction14, 16. In cultured fibroblasts from a patient with Leigh syndrome due to a genetic mutation in complex 
I, succinate prodrugs added in vitro to the cells improved mitochondrial respiration17.
The aim of the present study was to investigate whether succinate supplementation can rescue the energy state 
in rat mixed glial cells under experimental metabolic stress conditions using a defined inhibitor of mitochondrial 
function. Glia are especially relevant as clinical monitoring of TBI brain is performed via microdialysis catheters 
that are predominantly situated in white matter. In the present in vitro study, mixed glial cell cultures were isolated 
from neonatal Sprague Dawley rats. The cultured cells were exposed to rotenone, which is an inhibitor of complex 
I of the mitochondrial ETC, for periods of up to 24 h to induce conditions of metabolic stress, in the presence or 
absence of disodium succinate. Cellular response was determined by the measurement of intracellular ATP, extra-
cellular metabolites of clinical relevance (glucose, lactate, pyruvate), and the oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR). The mixed glial cultures were characterised by immunocytochemistry.
Results
Characterisation of mixed glial cultures. We first characterised our primary rat mixed (glial) cell culture 
model using immunocytochemistry. GFAP and GLT-1 were used as astrocyte markers, Isolectin as a microglia 
marker, and O4 as an oligodendrocyte markers (Fig. 1A). The cultures comprised predominantly of astrocytes (at 
around 55% of GFAP positive cells and 76% of GLT-1 positive cells), as well as microglia (approximately 21% of 
Isolectin-positive cells) and oligodendrocytes (approximately 14% of O4-positive cells) (Fig. 1B).
Figure 1. Characterisation of the cell populations present in the mixed glial cell cultures. Cells were stained 
for GFAP and GLT-1 (astrocyte markers), Isolectin (microglia marker) and O4 (oligodendrocyte marker). 
Representative images are shown in (A); total cell counts with the distribution of cell types is shown in (B).
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Mimicking metabolic stress in mixed glia cultures. To mimic metabolic features of TBI in vitro, meta-
bolic stress was induced by treatment of mixed glia cultures with rotenone, an inhibitor of complex I of the ETC. 
We first optimised our model by assessing the effects of varying concentrations of rotenone (up to 10 µM), which 
all resulted in a significant decrease of basal OCR to approx. 30% of the control rate. In contrast, levels of intra-
cellular ATP, measured after a 24 h incubation with increasing concentrations of rotenone remained comparable 
(data not shown). All subsequent experiments were conducted using 0.1 µM or 0.5 µM rotenone.
Effect of succinate on mitochondrial activity. Treatment with 0.1 µM rotenone induced an immedi-
ate reduction of OCR to approximately 1/3 of levels in controls (Fig. 2A). Following the addition of 6, 12 or 
24 mM succinate, OCR rate increased in both control wells and in cells treated with rotenone (n ≥ 3 wells per 
condition; Fig. 2). To confirm mitochondrial viability, the final step involved complete inhibition of oxidative 
metabolism by combinatorial treatment with rotenone/antimycin. Figure 2B represents the observed improve-
ments of mitochondrial activity induced by succinate, which resulted in an approximate 20% increase of OCR 
in rotenone-treated as well as control cells. The corresponding metabolic phenotype plot (Fig. 2C) also indicates 
shifts of the rotenone-treated cells and control cells to more energetic states as a result of addition of succinate. 
OCR indicates mitochondrial respiration, while ECAR is an indicator of glycolysis. Another source of extracellu-
lar acidification is CO2 production by mitochondria. For further explanation of OCR and ECAR see Divarakuni 
et al.18.
Effect of succinate on clinically relevant metabolite levels. The OCR experiments demonstrated 
an instantaneous effect of rotenone on mitochondrial function. To evaluate the dynamic response of mixed glial 
cultures to 0.5 µM rotenone alone, or in the presence of 6, 12 or 24 mM succinate, a time-course experiment was 
Figure 2. Effect of rotenone and succinate on oxygen consumption rate of mixed glia cultures. Oxygen 
consumption rate (OCR) was measured at 10 min intervals using a Seahorse Extracellular Flux XF24 analyser, 
in response to treatment with 0.1 µM rotenone (Rot; mitochondrial complex I inhibitor) (or regular assay 
medium in the control wells) followed by addition of succinate (Suc; 6, 12, 24 mM) and, finally, after oxidative 
metabolism is blocked by the addition of rotenone plus antimycin A (mitochondrial complex III inhibitor) in 
the final three measurements. (A) OCR profile over the course of the experiment; (B) Highlight of the effect of 
succinate on basal OCR under control conditions (addition of assay medium) and in the presence of succinate 
alone, 0.1 µM rotenone alone, or after the sequential addition of rotenone and different concentrations of 
succinate, as indicated. Statistically significant differences in OCR were observed between control samples 
and cells treated with succinate, rotenone, or succinate + rotenone for all succinate concentrations tested; 
furthermore, when comparing the ability of succinate to increase OCR after rotenone treatment, its effect at 
24 mM was significantly higher than that induced by 6 mM. A 2-way ANOVA followed by Tukey’s multiple 
comparisons test was used and simple effects within columns and rows were analysed. Statistical significance is 
denoted as follows: P ≤ 0.05 (*) and P ≤ 0.0001 (****). (C) Metabolic phenotype plot of OCR vs. extracellular 
acidification rate (ECAR). Data are from the same wells as in (A). Blue circle symbols indicate control wells: 
(1) basal conditions, (2) addition of control assay medium, (3) addition of 24 mM succinate, (4) addition of 
rotenone plus antimycin A. Orange square symbols indicate experimental wells: (1) basal conditions, (2) 
addition of 0.1 µM rotenone, (3) addition of 24 mM succinate, (4) addition of rotenone plus antimycin A. Units 
of OCR are picomol/min and ECAR milli-pH units/min; values are mean (n ≥ 3) ± standard error of the mean 
(s.e.m).
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conducted. Changes in extracellular metabolites were monitored every 4 hours over the course of 24 h (n = 3 
wells per condition; Fig. 3). Rotenone induced accelerated glucose depletion in the medium (Fig. 3A). This effect 
did not change in the presence of succinate. Rotenone treatment was also associated with higher concentrations 
of lactate in supernatants (Fig. 3B). In contrast, pyruvate levels were significantly lower in the wells treated with 
rotenone (Fig. 3C). The presence of succinate in the absence of rotenone resulted in increased pyruvate levels 
compared to control wells, suggesting an enhancement of mitochondrial activity by succinate. The most striking 
response was seen in the LPR, which is clinically considered the most reliable measure of metabolic stress within 
the injured brain (Fig. 3D). The LPR increased significantly with time in the presence of rotenone, showing the 
deterioration of the cells’ metabolic performance (Fig. 3D). On the other hand, succinate decreased the LPR in a 
concentration-dependent manner and this effect stayed constant with time, showing a sustained improvement of 
metabolic function, tested for up to 24 h.
Cell viability and expression of cellular markers. Cell death after treatment with rotenone and suc-
cinate for 24 h was determined by staining live cultures with propidium iodide (which labels the nuclei of dead 
cells), and calcein-AM (which stains viable cells in green after being converted to calcein). Figure 4A illus-
trates that the addition of 0.5 µM rotenone resulted in limited propidium iodide labelling of cells, comparable 
to control conditions and succinate-treated cells (n = 6 individual wells from 2 independent experiments). To 
assess the effects of rotenone and succinate on specific cell types, cells were labelled for GFAP and GLT-1 (astro-
cytes), isolectin (microglia), and O4 (oligodendrocyte precursor cells using immunocytochemistry (Fig. 4B,C). 
Rotenone treatment did not result in statistically significant differences amongst cell types (Fig. 4C).
Discussion
Mitochondrial dysfunction, where the brain is unable to utilise metabolic fuels and oxygen despite adequate 
provision, is thought to play a major role in the energy perturbations that occur following TBI. The aim of the 
present study was to investigate whether succinate treatment could improve cellular metabolism in a reductionist 
metabolic stress model, akin to the metabolic alterations observed in TBI patients after succinate treatment11.
Figure 3. Dynamic changes in extracellular metabolites after treatment with rotenone and succinate in mixed 
glia cultures. Samples of medium were collected at 4 h intervals during 24 h and extracellular metabolites were 
measured using a clinical microdialysis analyser (ISCUSflex) in response to 0.5 µM rotenone treatment, with 
or without succinate (6, 12, 24 mM) supplementation. The average concentrations of the metabolites glucose, 
lactate and pyruvate are shown in (A), (B), and (C), respectively. The lactate/pyruvate ratio (LPR) is shown in 
(D). Values are the mean of n = 3 (each measured in duplicate), ±standard error of the mean (s.e.m.). A total of 
3 independent samples are shown from one representative experiment (further results not shown). Statistically 
significant differences were observed between samples treated with rotenone and controls (1-way ANOVA), and 
between samples with or without succinate (paired sample t-test). Statistical significance is denoted as follows: 
P ≤ 0.001 (***) and P ≤ 0.0001 (****).
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To model mitochondrial dysfunction in brain, primary rat mixed glial cell cultures were treated with rotenone 
to induce metabolic stress. The cultures consisted predominantly of astrocytes, next to oligodendrocyte lineage 
cells and microglia. Our model enabled studying mitochondrial dysfunction, induced by rotenone-mediated 
inhibition of complex I. This is specifically relevant to brain injury without ischaemia, where the susceptibil-
ity of complex I in the mitochondrial transport chain to sustain damage is thought to play a major role10. Our 
reductionist approach enabled assessment of the remaining metabolic capacity, and the possible metabolic “res-
cue”-type function of succinate administration. We specifically assessed changes in oxygen consumption rate 
(OCR), intracellular ATP, and in the levels of the extracellular metabolites glucose, lactate, pyruvate, and lactate 
in response to rotenone treatment and after succinate administration.
We observed a significant reduction in OCR following rotenone treatment at concentrations ranging from 0.1 
to 10 µM. This confirmed significant mitochondria dysfunction, even at low concentrations of rotenone. Glucose, 
pyruvate and lactate are metabolites regularly measured in the brain extracellular fluid of TBI patients in a clinical 
setting to establish phenotypes that can be correlated with a favourable or unfavourable outcome. Mixed glial 
cultures exposed to rotenone exhibited abnormalities in glucose, lactate and pyruvate levels which represent the 
Figure 4. Effect of rotenone and succinate on cell viability and expression of cellular markers. (A) Percent 
of total cells stained with propidium iodide (dead cells) and calcein (viable cells) after 24 h of treatment with 
succinate and/or 0.5 µM rotenone v. control conditions. (B) Percent of total cells expressing the different cellular 
markers (GFAP, GLT-1, isolectin and O4) after 24 h of succinate treatment, with or without 0.5 µM rotenone. All 
values in A and B are mean ± standard error of the mean (s.e.m.) of >500 cells analysed (n = 6 individual wells 
from 2 independent experiments). The expression of cellular markers did not change significantly with rotenone 
or succinate treatment. (C) Images of the mixed glial cells stained with the markers DAPI (grey), GFAP (green), 
GLT-1 (red), isolectin (red) and O4 (red) after 24 h of succinate treatment, with or without 0.5 µM rotenone.
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main metabolic features previously described in TBI patients. A cellular model of this type has not previously 
been described within the field of brain metabolism and could be very valuable to the study of metabolic interac-
tions not just in an injured state, but also within a healthy and functioning glial cell system.
Our initial experiments established that cultures were able to partially compensate rotenone-induced meta-
bolic stress and maintain ATP levels in the 24 h time-frame of the experiments. This may result from the capac-
ity of glial cells to increase glycolysis or autophagy for producing ATP19. In fact, it has been demonstrated that 
astrocytes can generate lactate from glycogen via glycolysis under conditions of metabolic activation, including 
hypoglycemia and increased neuronal activity20–22.
In a clinical setting, increased extracellular (microdialysate) lactate versus pyruvate, expressed in an increased 
LPR can be indicative of impaired oxidative metabolism in TBI patients3, 5, 7, 23. Hillered et al. identified two pos-
sible circumstances which can lead to LPR elevation clinically23. The first is classical ischaemic metabolic state 
characterised by increased lactate due to anaerobic metabolism, which is accompanied by markedly low pyruvate. 
In the second, pyruvate is diminished in the absence of ischaemia, indicating metabolic disturbance. The latter is 
considered as associated with mitochondrial dysfunction. Recently Nordström et al. have highlighted that tran-
sitions can occur within-patient between ischaemia-pattern and mitochondrial dysfunction-pattern (and vice 
versa), with time post-injury, and that in the transition from ischaemia-pattern to mitochondrial dysfunction, 
pyruvate can rise with time7. In patients with TBI, the mitochondrial dysfunction pattern of LPR elevation is seen 
more often than ischaemic pattern5, 7. In our cell culture model, LPR elevation is a result of rotenone treatment 
that inhibits mitochondrial ETC complex 1, producing significantly elevated lactate levels, as well as reduced 
pyruvate levels, which contributed to an increase in the LPR in rotenone-treated cells. Furthermore, rotenone 
treated cells consumed more glucose compared to controls over the course of 24 h (Fig. 4A). This likely reflects the 
capacity of the glial cells to increase their metabolism of glucose via glycolysis to compensate for energy deficits 
in mitochondrial oxidative metabolism.
The main goal of the present work was to assess to what extent the administration of succinate could improve 
mitochondria function after rotenone treatment. The addition of succinate (with or without rotenone treatment) 
improved OCR by approximately 20% (Fig. 2). Since the same extent of increase in OCR was observed for healthy 
control cells (not pre-treated with rotenone), we hypothesize that there might be a limiting factor regarding the 
ability of succinate to improve OCR. A possible explanation could be a limitation on the availability of additional 
TCA cycle intermediates, such as acetyl-CoA, whose concentration was likely decreased in rotenone-treated cells 
due to the preferential use of pyruvate towards lactate production. Oxaloacetate formed after succinate metabo-
lism needs to condense with a molecule of acetyl-CoA for the TCA cycle to function and, consequently, further 
increase the flux of electrons in the ETC. A further consideration is that since the OCR assay was performed in a 
short time-frame (approx. 2 h), we cannot exclude that the effect of succinate on OCR could have been more pro-
nounced if cells were exposed longer to succinate. The Seahorse Flux analyser gives an OCR reading per well of 
cells (mixed glia), and this technology cannot differentiate the individual responses of the various glial sub-types 
present within the same well. Determining whether there are any differences between the glial sub-types in terms 
of their OCR in response to rotenone and/or succinate would need dedicated studies of the isolated sub-types.
Succinate yielded a significant decrease in LPR in rotenone-treated cells (Fig.  3D). This 
concentration-dependent effect remained constant with time, showing a sustained improvement of metabolic 
function, tested for up to 24 h. Decrease in LPR in succinate-treated wells resulted from a reduction in lactate 
production and an increase in pyruvate levels compared to cells treated with rotenone only (Fig. 3).
All these metabolic changes occurred in cultures with overall viable cells. Nevertheless, the cell loss that 
occurred and the changes of cell morphology in cultures treated with rotenone indicates a clear cellular response 
to the induced metabolic stress.
Our in vitro findings are comparable to those in vivo. Jalloh et al.11 tested the hypothesis that 2,3-13C2 succinate 
(disodium salt) administered by cerebral microdialysis in TBI patients would be metabolised and enhance the 
TCA cycle. The measurement of the resulting 13C-labelled metabolites, exported from cells into the interstitium 
and taken up through the microdialysis catheter for analysis, provided definitive proof that the 2,3-13C2 succi-
nate administered had been metabolised via the TCA cycle11. Jalloh et al. also reported a lower LPR after focal 
succinate administration, suggesting an improvement in the mitochondrial function of the cells, even under the 
metabolically stressful conditions invoked by injury11. Use of succinate to support mitochondrial respiration was 
performed in the presence of adequate oxygenation and not in ischaemia-reperfusion11. Our reductionist in vitro 
glial model adds further support to TBI findings in vivo.
In conclusion, we have shown that mixed glia cultures respond metabolically to stress induced by rotenone. 
This is reflected in changes in the LPR and OCR. Moreover, we have shown that succinate is able to improve 
mitochondria function up to 20% in a sustained manner in mixed glial cultures, consistent with our other studies 
in succinate-treated focal areas of injured human brain11. Our reductionist model of glial mitochondrial stress 
therefore has potential applicability to devising and evaluating rescue treatments for mitochondrial dysfunction 
and may pave the way for novel treatments, e.g. administration of succinate, for head injury and for various other 
conditions associated with mitochondrial dysfunction. Such conditions include neurodegenerative diseases and 
ageing-related diseases such as dementias and Parkinson’s, which often manifest at a younger age in brain injury 
survivors compared to individuals without any previous brain injury24–26.
Materials and Methods
Reagents. Cell culture reagents were purchased from Sigma (Dorset, UK): (Dulbeccos’ Modified Eagle’s 
Medium (DMEM), L-Glutamine, poly-L-lysine (PLL), papain); or from Life Technologies (Paisley, UK) (fetal 
bovine serum (FBS), fetal calf serum (FCS), penicillin-streptomycin 100x (Pen-Strep)). All other chemicals were 
of the purest grade available from Sigma (Dorset, UK) unless otherwise stated.
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Primary mixed glia cell cultures. Primary mixed glia cultures were isolated from P0 to P2 neonatal 
Sprague-Dawley rat forebrains as previously described27. Neonatal rats were euthanized according to “Schedule 1” 
regulations from the Home Office Animal Procedures Committee UK and the cortices removed. After removing 
the meninges, tissues were digested using a papain solution and the resulting cell suspensions were seeded in T75 
flasks at a density of 2 brains/flask. Cells were cultured in DMEM containing 6 mM glucose and 4 mM glutamine, 
1% (v/v) Pen/Strep and 10% (v/v) FBS and medium was changed every 3–4 days. Cells were kept in a humidified 
incubator at 37 °C under an atmosphere containing 7% CO2 in air. After a minimum of 15 days in culture, cells 
were collected using trypsin-EDTA and re-plated in PLL-coated 6- or 24-well cell culture plates for subsequent 
experiments at a density of 4.2 × 104 cells/cm2.
Mitochondrial dysfunction experiments. Mitochondrial dysfunction was induced in mixed glial cul-
tures using rotenone, an inhibitor of the complex I of the ETC. When cells reached 80% confluence, the medium 
was changed to a phenol-red free DMEM (prepared from powdered DMEM from Sigma-Aldrich, cat. no. D5030) 
containing 6 mM glucose, 1% (v/v) Pen-Strep (final concentrations 100 Units/ml penicillin and 100 µg/ml strep-
tomycin), 1% (v/v) FBS and 0.1, 0.5, 1.0 or 10 µM rotenone and cells were incubated for 24 h. In some wells, suc-
cinate at 6, 12 or 24 mM was also added with the aim of assessing its role in improving mitochondrial function in 
the presence of rotenone. Control wells were incubated with the regular phenol-red free DMEM with or without 
succinate (6–24 mM). In the 24 h end-point experiments, the medium was collected at the end of the incubation 
period and saved for metabolite analyses. In the time-course experiments (performed in 6-well plates), samples 
of medium were collected every 4 h and stored at −20 °C until further analysis. At the end of the experiments, 
cells were either stained for cell viability assays or washed twice with PBS and fixed for subsequent immunocy-
tochemistry analysis, or lysed for ATP quantification or protein analysis, according to the protocols described 
below. A minimum of two independent experiments was performed with cells from independent rat litters for 
each condition tested, using 3 biological replicates per experiment.
Metabolite Analysis. Samples of culture medium were filtered using 0.45 µm PVDF syringe filter units 
(Whatman). Quantitative analysis for glucose, lactate and pyruvate was performed using an ISCUSflex microdi-
alysis analyser (M Dialysis AB, Stockholm, Sweden). Two repeat measurements were performed per sample. Data 
were analysed using M Dialysis LABpilot, Microsoft Excel and OriginLab Origin software.
Cell viability analysis. Cell viability was assessed in live cells using the cell permeant dye Calcein-AM (Life 
Technologies, Paisley, UK) (viable cells convert it to Calcein which emits green fluorescence) and propidium 
iodide (PI) (Life Technologies, Paisley, UK), which enters the nuclei of dead cells, making them fluoresce in red. 
The dyes were added directly to the cell culture medium: 100 µg/ml of PI solution and 0.6 µM Calcein-AM. After 
10 minutes’ incubation at 37 °C, Hoechst 33342 at 5 µg/ml was added to the cells to stain the nuclei. Cells were 
imaged directly using an IN Cell 2000 Analyser (GE Healthcare, Little Chalfont, UK) in three random fields per 
well at 20x magnification. The filters used to visualize the different fluorophores were: FITC for calcein, Texas 
Red for PI and DAPI for Hoescht. The number of dead cells was determined based on the number of PI-positive/
Hoechst positive cells and the number of viable cells was given by the ratio Calcein-positive/Hoechst-positive 
cells. Data are shown as percent of the total number of cells given by Hoechst staining.
Measurement of cellular oxygen consumption rate (OCR). Cellular oxygen consumption rate (OCR) 
was measured using a Seahorse XF24 extracellular flux analyser (Seahorse Biosciences, Denmark). Cells were 
seeded at a density of 7–10 × 104 cells/well in poly-L-lysine (PLL)-coated XF24 plates and cultured under the 
conditions described above. The assay was performed when cells reached confluence. Cells were incubated in 
assay medium (DMEM with all the regular supplements, but minus sodium bicarbonate and phenol red) for at 
least 30 min prior to the assay under a low CO2 environment (XF24 incubator attached to the XF24 analyser). 
OCR was measured every 5 minutes for three times under basal conditions, after which medium with rotenone, 
or unsupplemented medium (for the control wells) were added to the culture wells. Three further measurements 
were then taken before a solution of succinate (disodium salt) at different concentrations (6, 12 and 24 mM) was 
added to all wells (including controls). In the last step of the assay, 10 μM rotenone + 10 μM antimycin A (inhib-
itors of mitochondrial complex I and III, respectively) were added to all wells to confirm that the OCR measured 
was due to mitochondrial respiration (negative control readings). Extracellular acidification rate (ECAR) was also 
measured on the Seahorse XF24 analyser simultaneously with the OCR measurements in the same wells.
Quantification of intracellular ATP. Intracellular ATP content was determined using the ATPliteTM 1step 
kit (Perkin Elmer, Waltham, MA, USA) in lysed cells, according to the manufacturer’s instructions. Luminescence 
intensity from each well was measured using a GloMax 96 Luminometer microplate reader (Promega, 
Southampton, UK). Quantification of ATP was made by interpolation from an ATP standard curve made of 
10-fold serial dilutions of a 1 µM ATP standard solution. ATP results were normalised by expressing them relative 
to cellular protein concentration (see below). Data were analysed on Microsoft Excel and OriginLab Origin.
Protein Assay. Total protein content was determined using the colorimetric Pierce BCA protein assay kit 
(Thermo Fisher, Scientific, Waltham, MA) in cell pellets, according to the manufacturer’s instructions. Briefly, 
cells were washed with PBS, collected with trypsin from the cell culture plates and centrifuged to obtain cell pel-
lets, which were then lysed using RIPA lysis buffer (Sigma, Dorset, UK). Absorbance was measured using a Wallac 
EnVision 2104 Multilabel Reader (Perkin Elmer, Waltham, MA) at 560 nm. Quantification of total protein was 
determined by interpolation from a standard curve made of 2-fold serial dilutions of a 2 mg/mL bovine serum 
albumin (BSA) standard solution. Results were calculated using Microsoft Excel and Originlab Origin software.
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Immunocytochemistry. After the mitochondrial dysfunction experiments, cells were fixed with paraform-
aldehyde (PFA) 4% (v/v) in PBS for 10 min, followed by two washes with PBS. Fixed cells were permeabilized with 
0.02% saponin and blocked with 10% normal goat serum prior to incubation with the following primary antibod-
ies overnight at 4 °C: anti-O4 mouse monoclonal antibody (1:1000; R&D Systems, Minneapolis, MN), anti-GFAP 
rabbit polyclonal antibody (1:500; Dako), anti-GFAP mouse monoclonal antibody (1:300; AbCam, Cambridge, 
UK), anti-Isolectin-594 conjugated antibody (1:300; Life Technologies), anti-EAAT-1 rabbit polyclonal antibody 
(1:500; AbCam, Cambridge, UK). Secondary antibodies conjugated with Alexa Fluor 488, Alexa Fluor 594 or 
Alexa Fluor 647 were used to visualize positive cells (1:500; Life Technologies). The nuclei were stained using 
DAPI (Life Technologies). Following immunocytochemistry, cells were mounted with Prolong gold anti-fade 
mounting medium (Life Technologies). Cells were visualised and images acquired using a Zeiss LSM 700 confocal 
microscope (Zeiss, Thornwood, NJ) at 20x magnification using the Zen Application software. For cells stained 
directly on cell culture plates, images from three random fields were acquired per well using an IN Cell Analyser 
2000 (GE Healthcare, Little Chalfont, UK) microscope at 20x magnification. For quantitative analyses, the per-
centage positive cells for a given antigen relative to >200 DAPI-stained nuclei per experiment was determined in 
randomly selected visual fields.
Statistical analysis. Data are shown as mean ± S.E.M. values from samples obtained from at least two 
independent experiments or, for time-course experiments, data from one representative experiment is provided, 
with statistics performed for the biological replicates used (n = 3). Data were analysed by two-way ANOVA fol-
lowed by Tukey’s means comparison post-hoc test (to compare rotenone treated with control samples), or using 
Student’s paired T-test to compare the effect of succinate vs non-succinate. Calculations were performed using the 
statistical software package OriginLab Origin. Differences were considered significant when p < 0.05.
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